HA Injection Evidence (Supartz Trial)

→ A Supartz injection is recorded in May 2026, but the response is not yet documented. HA is symptom treatment, not cartilage repair, and evidence from knee OA does not automatically apply to this postoperative ankle lesion.

Expected Duration of Relief

• 4-6 months is the most consistently reported duration of meaningful pain relief per series across studies [181]
• Hwang et al. (2020): VAS significantly reduced at 12 months in HA after failed microfracture; AOFAS 50.7 → 79.9 at mean 29 months [182]
• For Hepple V cystic lesions, durability is typically at the shorter end because HA does not address subchondral bone pathology

Repeat Dosing: Evidence Is Mostly From Knee OA

The AMELIA Project studied 4 cycles of 5 HA injections over 40 months in 306 people with knee osteoarthritis, not ankle OLT [183]:

• The knee cohort reported a carry-over effect and no new safety signal across repeated cycles
• Large real-world knee data associated more courses with longer time before total knee arthroplasty, but cannot establish cause and effect in an ankle [184]
• These studies do not establish unlimited repeat dosing or durable effectiveness for this ankle
• The July 2026 AAOS guideline strongly recommends against HA alone for symptomatic ankle osteoarthritis; focal postoperative OLT is not identical to diffuse OA, so an individual's measured response still matters [AAOS 2026]

August 2026: The Kennedy Group Reads the Same Evidence and Lands Softer Than AAOS

Published 2026-08-14, the day before this entry — a scoping review of HA across foot and ankle pathology from the NYU Langone foot-and-ankle division, senior author John G. Kennedy, one of the most-published surgeons in talar cartilage [422]. It matters here because it separates the evidence by indication rather than lumping the ankle together:

• The most consistent evidence is for soft-tissue conditions — Achilles tendinopathy, plantar fasciitis, acute lateral ankle injury. Not this lesion.
• For OLT and selected OA, HA is positioned as an adjunct, with outcomes stated plainly as “heterogeneous across studies.”
• The stated limits are the familiar ones: heterogeneous designs, inconsistent protocols, short follow-up — and the paper is Level V, a scoping review, the weakest evidence class on this page.

How this sits against the July 2026 AAOS guideline above: it does not overturn it and does not try to. AAOS graded HA alone for symptomatic ankle OA and recommended strongly against it; this review is looking at a wider set of indications and reaches “adjunct, in selected cases, evidence limited.” Both statements can be true at once, and neither is data about a post-allograft Hepple V lesion. What it changes in practice is small and real: the framing to bring to the August 18 appointment is not “HA versus nothing” but “HA as an adjunct, with a pre-set failure threshold” — which is exactly what the failure criteria below already specify.

Product Comparison — If Supartz Wanes

Supartz is mid-MW linear HA. If response diminishes, options include:

• Cross-linked HMW products (Synvisc-One, Monovisc, Durolane): potentially longer intra-articular residence, but higher rate of post-injection flare reactions (~2.5%)
• Euflexxa: bio-fermented (non-avian), higher MW, useful if avian allergy concern
• No head-to-head ankle data shows clear product superiority — the Witteveen Cochrane review found similar modest benefits across products [185]

Predictors of Response (Han 2014)

Yonsei Medical Journal study of 40 patients found [186]:

• Positive predictors: early-stage disease (Takakura I-II), symptom duration <12 months
• NOT predictive: age, gender, fracture history, subchondral cysts
• 12-month outcomes: 40% completely satisfied, 35% dissatisfied

Failure Criteria — When to Escalate

• Set MCID thresholds before each series (AOFAS ≥10 points, VAS ≥2 points)
• If <3 months of meaningful relief per series, or ≥2 failed series → consider next-line
• Hwang 2020: 33% of HA-after-failed-microfracture patients went on to further surgery within mean 29 months
• For Hepple V: failure criteria should be tighter because HA can't fix the underlying bone problem

Off-Label Use and Insurance Reality

• FDA-approved for KNEE OA only. ALL ankle use is off-label
• Medicare LCD L39260 and most commercial insurers: HA "investigative and not covered" for ankle
• Most common outcome: denial. Patients pay cash ($300-$1200 per injection)
• Switching from Kaiser to PPO may help with appeal-based coverage but doesn't change FDA off-label status
• Boffa/Filardo 2021 systematic review (24 studies): significant benefit favoring HA vs saline at 6 months for ankle OA, GRADE evidence quality "very low" [187]

Combination Therapies Worth Considering

• HA + PRP: Mei-Dan 2012 head-to-head — PRP slightly superior to HA alone for talar OLT (VAS 4.1→0.9 PRP vs 5.6→3.1 HA) [188]
• HA + BMAC + scaffold: Buda 10-year data shows durable results for cystic OLT (this is surgical, not injection) [189]
• HA + corticosteroid: Avoid in young patient — steroid is chondrotoxic with repeated use

Long-Term Safety

• Per-injection AE rate: 1-4%; serious AEs <0.01%
• Repeated courses are at least as safe, probably safer than first course
• No cumulative toxicity, no chondrotoxicity (unlike corticosteroids)
• Main risk is opportunity cost — delaying definitive treatment of a Hepple V cystic lesion